intention to treat analysis

(redirected from intent to treat analysis)

intention to treat analysis

An analysis in which all trial participants are analysed according to the intervention to which they were allocated, whether they received that therapy or not. Such analyses are favoured in assessing effectiveness, as they mirror non-compliance and treatment changes likely to occur when the intervention is used in practice, and because of the risk of attrition bias when participants are excluded from the analysis.

intention to treat analysis

, intent to treat analysis
A clinical trial in which results from all randomized patients are included whether or not they actively participated in the complete study.
References in periodicals archive ?
The highest proportion of subjects achieving PGA Success in the Intent to Treat analysis occurred at Day 42 with 26% of subjects in the AN2728 arm (n=46) achieving PGA Success compared to 18% in the vehicle arm (n=22).
Observed cases analysis using data on completers-a cherry-picked population-will almost inevitably have more positive results than an intent to treat analysis of all patients, including scores of dropouts at the time of attrition (last observation carried forward, or LOCF).
By intent to treat analysis at 48 weeks, 47% of patients in group C (quadruple therapy) had viral loads less than 50 copies/mL compared to 42%, 38% and 26% for groups A, B and D, respectively.
A subject is valid for per protocol analysis, if the subject: is (1) valid for modified intent to treat analysis and (2) has an adequate assessment of VTE that was done not later than a pre-defined period after stop of study drug (to be determined prior to unblinding and documented) and (3) met the inclusion criteria regarding medical illness and VTE risk factors and (4) shows no major protocol deviations.
A subject is valid for modified intent to treat analysis, if the subject: (1) is valid for safety analysis and (2) has an adequate assessment of VTE.
Blood samples that were taken every 2 weeks showed that the supplement significantly slowed the rate of PSA increase in both an intent to treat analysis of 46 patients who had at least two serum PSA readings per treatment and an analysis of 42 patients who had five PSA readings per treatment as called for in the protocol.
In a modified intent to treat analysis which included all patients with at least one evaluable study radiograph and a minimum of one dose of study drug or placebo, toremifene citrate 80 mg demonstrated a 50% reduction in morphometric vertebral fractures (p<0.
Those results were consistent between both trials despite different geographical study sites and chemotherapy regimens on the intent to treat analysis.
Although all of the ERGOSET(R) and placebo groups lost weight during the study, there was no statistically significant difference in weight loss between patients treated with ERGOSET(R) tablets and diet and patients treated with placebo and diet in the intent to treat analysis.